[DOI] [PubMed] [Google Scholar] 121.Lentjes M.A., Welch A.A., Keogh R.H., Luben R.N., Khaw K.T
Health Journey GLP-1 Booster positions itself in a unique space: a gut-first formula targeting natural GLP-1 signaling
Clinical data primarily from dermatological topical studies
FDA Approves Mounjaro for Weight Loss Use, to Be Sold Under New Zepbound Name Approval comes amid growing reports of stomach paralysis from Mounjaro, Ozempic and similar drugs, which have led to a number of lawsuits over failure to warn about the potential side effects Federal regulators have granted approval for a weight loss version of the Eli Lilly diabetes drug Mounjaro, which will be marketed under the brand name Zepbound, despite growing concerns over the adequacy of existing warnings about potential stomach paralysis side effects linked to Ozempic, Wegovy and other similar drugs
To further assess the varying relationship of metabolites with eGFR we computed boosted trees models predicting eGFR with serum metabolomics as the input variable, with a similar methodology to TMAO
